Article
Oncology
Alok A. Khorana, Jennell Palaia, Lisa Rosenblatt, Radhika Pisupati, Ning Huang, Chi Nguyen, John Barron, Kerrin Gallagher, T. Christopher Bond
Summary: This study assessed the incidence and risk factors of venous thromboembolism (VTE) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI). The study found that ICI-based regimens were associated with lower risk of VTE compared to chemotherapy (chemo), while the risk of VTE with ICI+chemo regimens was similar to chemo. Previous radiation and severe obesity were also associated with VTE.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Myrto K. Moutafi, Weiwei Tao, Richard Huang, James Haberberger, Brian Alexander, Shakti Ramkissoon, Jeffrey S. Ross, Konstantinos Syrigos, Wei Wei, Lajos Pusztai, David L. Rimm, Ioannis A. Vathiotis
Summary: Metastatic lesions tend to have higher PD-L1 expression levels compared to primary lesions, with variation based on histologic subtype, sampling site, and gender. This observation may impact future patient management and trial design.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Bruce C. Tiu, Leyre Zubiri, James Iheke, Vartan Pahalyants, Nicholas Theodosakis, Pearl Ugwu-Dike, Jayhyun Seo, Kimberly Tang, Meghan E. Sise, Ryan Sullivan, Jarushka Naidoo, Meghan J. Mooradian, Yevgeniy R. Semenov, Kerry L. Reynolds
Summary: The use of PD-1/PD-L1 inhibitors in lung cancer patients increases the risk of developing CIP. Patients with CIP require more healthcare resources, have a higher rate of discontinuation of ICIs, and face an increased risk of mortality.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J. Blackburn, Stephen Capone, Kathryn B. Bollin, Daniel Y. Reuben, Keisuke Shirai, Sandy Zhang-Nunes, Omar Ragab, Alicia Terando, Jenny C. Hu, Han Lee, Shailender Bhatia, Sunandana Chandra, Jose Lutzky, Geoffrey Thomas Gibney
Summary: This study conducted a multicenter, retrospective analysis of BCC patients treated with PD-1 inhibitor therapy, demonstrating good efficacy and safety. Some patients achieved partial or complete responses with PD-1 inhibition.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar
Summary: This study of 125 patients suggests a positive impact of ICI on overall survival in aLCNEC, despite the limitations of retrospective design and small sample size.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Justin Ferdinandus, Martin Metzenmacher, Lukas Kessler, Lale Umutlu, Clemens Aigner, Kambartel Otto Karl, Viktor Gruenwald, Wilfried Eberhardt, Wolfgang Peter Fendler, Ken Herrmann, Martin Faehling, Daniel Christian Christoph
Summary: After a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Jiaxin Liu, Lingyun Wei, Nan Hu, Dong Wang, Juan Ni, Sha Zhang, Hongbing Liu, Tangfeng Lv, Jie Yin, Mingxiang Ye, Yong Song
Summary: This study reveals the critical role of FBW7 in determining the stability of PD-1 protein and demonstrates that targeting FBW7 can enhance anti-tumor immunity. In addition, the study found that the expression level of FBW7 can predict the clinical response to anti-PD-1 immunotherapy in NSCLC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Marie Wislez, Julien Mazieres, Armelle Lavole, Gerard Zalcman, Olivier Carre, Thomas Egenod, Raffaele Caliandro, Catherine Dubos-Arvis, Gaelle Jeannin, Olivier Molinier, Marie-Ange Massiani, Alexandra Langlais, Franck Morin, Francoise Le Pimpec Barthes, Laurent Brouchet, Jalal Assouad, Bernard Milleron, Diane Damotte, Martine Antoine, Virginie Westeel
Summary: This study assessed the feasibility of neoadjuvant durvalumab for early-stage resectable non-small-cell lung cancer. The results showed that this treatment approach resulted in a high complete resection rate and some pathological response. However, the unexpectedly high postoperative mortality rate led to the premature termination of the study.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Myrto K. Moutafi, Magdalena Molero, Sandra Martinez Morilla, Javier Baena, Ioannis A. Vathiotis, Niki Gavrielatou, Laura Castro-Labrador, Gorka Ruiz de Garibay, Vera Adradas, Daniel Orive, Karmele Valencia, Alfonso Calvo, Luis M. Montuenga, S. Ponce Aix, Kurt A. Schalper, Roy S. Herbst, Luis Paz-Ares, David L. Rimm, Jon Zugazagoitia
Summary: This study identifies CD44 as a novel biomarker for predicting sensitivity to PD-1 axis blockade in NSCLC, and validates its correlation with prolonged progression-free survival and overall survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, Ila J. Datar, Mari Mino-Kenudson, German Corredor, Cristian Barrera, Lindsey Behlman, David L. Rimm, Roy S. Herbst, Anant Madabhushi, Jonathan W. Riess, Vamsidhar Velcheti, Matthew D. Hellmann, Justin Gainor, Kurt A. Schalper
Summary: Baseline T cell density and exhaustion marker expression can stratify outcomes in PD-L1 positive patients with NSCLC treated with ICI. Spatial immune heterogeneity can be measured using the RQI and is associated with survival in NSCLC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Zaishang Li, Xueying Li, Wayne Lam, Yabing Cao, Hui Han, Xueqi Zhang, Jiequn Fang, Kefeng Xiao, Fangjian Zhou
Summary: Comparing anti-PD-1 and anti-PD-L1 therapies in platinum-resistant UC patients reveals that anti-PD-1 therapy exhibits better antitumor activity, with comparable safety profiles and survival outcomes. This systematic comparison may enhance treatment awareness in this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Paul Sackstein, Jacob Zaemes, Chul Kim
Summary: This case emphasizes the importance of considering CRS in patients who develop multiorgan failure after immune checkpoint inhibitor therapy, and demonstrates clinical similarities between CRS and other hyperinflammatory states such as hemophagocytic lymphohistiocytosis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Jianli Zhao, Zhixian Sun, Yunfang Yu, Zhongyu Yuan, Ying Lin, Yujie Tan, Xiaohui Duan, Ying Wang, Herui Yao, Jieqiong Liu
Summary: A radiomics model was developed to accurately predict the response of patients with advanced breast cancer to immune checkpoint inhibitors (ICIs). The model outperformed the clinical model and was able to classify patients into high-risk and low-risk groups.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Samuel Peter Heilbroner, Reed Few, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus, Tomas G. Neilan
Summary: The study used a machine learning model to predict cardiac events risk factors in patients receiving immune checkpoint inhibitors therapy, including increased age, corticosteroids, laboratory abnormalities, cardiac history, extremes of weight, decreased lymphocyte percentage, and increased neutrophil percentage.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Philip A. Friedlander, Adil Daud, Harriet M. Kluger, Sunil A. Reddy, Brian C. Boulmay, Adam Riker, Melissa A. Burgess, Brent A. Hanks, Thomas Olencki, Kari Kendra, Candice Church, Tomoko Akaike, Nirasha Ramchurren, Michi M. Shinohara, Bob Salim, Janis M. Taube, Erin Jensen, Mizuho Kalabis, Steven P. Fling, Blanca Homet Moreno, Elad Sharon, Martin A. Cheever, Suzanne L. Topalian
Summary: In this study, the use of pembrolizumab in Merkel cell carcinoma patients showed a 58% overall response rate and a 39.1% 3-year progression-free survival rate. Patients with specific baseline factors and completion of 2 years of treatment were associated with better response and longer survival. Some patients experiencing disease progression or relapse following response had extended survival with salvage therapies including chemotherapies and immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Respiratory System
Renata L. Riha, Marta Celmina, Brendan Cooper, Refika Hamutcu-Ersu, Athanasios Kaditis, Andrew Morley, Athanasia Pataka, Thomas Penzel, Luca Roberti, Warren Ruehland, Dries Testelmans, Annelies van Eyck, Gert Grundstroem, Johan Verbraecken, Winfried Randerath
Summary: For over three decades, type III devices have been used to diagnose sleep disordered breathing. While they are satisfactory in detecting obstructive and central sleep apnoea in populations with moderately high risk of symptoms, these devices lack standardization and can vary greatly in technical specifications. This technical standard summarizes type III studies published since 2007, aiming to provide a framework for considering the limitations and improving the use of these devices in the diagnosis of sleep disordered breathing.
EUROPEAN RESPIRATORY JOURNAL
(2023)
Article
Clinical Neurology
Bertien Buyse, Pascal Borzee, Alexandros Kalkanis, Dries Testelmans
Summary: The American Academy of Sleep Medicine (AASM) uses similar apnea-hypopnea index (AHI) cut-off values to diagnose and define the severity of sleep apnea. This study explored whether a lower cut-off value would be more appropriate. The results suggest that using a lower cut-off value could lead to cost savings and reduce the number of negative studies.
JOURNAL OF SLEEP RESEARCH
(2023)
Article
Genetics & Heredity
Stefanie H. Mueller, Alvina G. Lai, Maria Valkovskaya, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang, Joe Dennis, Michael Lush, Zomoruda Abu-Ful, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Volker Arndt, Kristan J. Aronson, Annelie Augustinsson, Thais Baert, Laura E. Beane Freeman, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Carl Blomqvist, Natalia Bogdanova, Stig E. Bojesen, Bernardo Bonanni, Hermann Brenner, Sara Y. Brucker, Saundra S. Buys, Jose E. Castelao, Tsun L. Chan, Jenny Chang-Claude, Stephen J. Chanock, Ji-Yeob Choi, Wendy K. Chung, Sarah Colonna, Sten Cornelissen, Fergus J. Couch, Kamila Czene, Mary B. Daly, Peter Devilee, Thilo Dork, Laure Dossus, Miriam Dwek, Diana M. Eccles, Arif B. Ekici, A. Heather Eliassen, Christoph Engel, D. Gareth Evans, Peter A. Fasching, Olivia Fletcher, Henrik Flyger, Manuela Gago-Dominguez, Yu-Tang Gao, Montserrat Garcia-Closas, Jose A. Garcia-Saenz, Jeanine Genkinger, Aleksandra Gentry-Maharaj, Felix Grassmann, Pascal Guenel, Melanie Gundert, Lothar Haeberle, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Per Hall, Elaine F. Harkness, Patricia A. Harrington, Jaana M. Hartikainen, Mikael Hartman, Alexander Hein, Weang-Kee Ho, Maartje J. Hooning, Reiner Hoppe, John L. Hopper, Richard S. Houlston, Anthony Howell, David J. Hunter, Dezheng Huo, Abctb Investigators, Hidemi Ito, Motoki Iwasaki, Anna Jakubowska, Wolfgang Janni, Esther M. John, Michael E. Jones, Audrey Jung, Rudolf Kaaks, Daehee Kang, Elza K. Khusnutdinova, Sung-Won Kim, Cari M. Kitahara, Stella Koutros, Peter Kraft, Vessela N. Kristensen, Katerina Kubelka-Sabit, Allison W. Kurian, Ava Kwong, James Lacey, Diether Lambrechts, Loic Le Marchand, Jingmei Li, Martha Linet, Wing-Yee Lo, Jirong Long, Artitaya Lophatananon, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Keitaro Matsuo, Dimitrios Mavroudis, Usha Menon, Kenneth Muir, Rachel A. Murphy, Heli Nevanlinna, William G. Newman, Dieter Niederacher, Katie M. O'Brien, Nadia Obi, Kenneth Offit, Olufunmilayo Olopade, Andrew F. Olshan, Hakan Olsson, Sue K. Park, Alpa Patel, Achal Patel, Charles M. Perou, Julian Peto, Paul D. P. Pharoah, Dijana Plaseska-Karanfilska, Nadege Presneau, Brigitte Rack, Paolo Radice, Dhanya Ramachandran, Muhammad U. Rashid, Gad Rennert, Atocha Romero, Kathryn J. Ruddy, Matthias Ruebner, Emmanouil Saloustros, Dale P. Sandler, Elinor J. Sawyer, Marjanka K. Schmidt, Rita K. Schmutzler, Michael O. Schneider, Christopher Scott, Mitul Shah, Priyanka Sharma, Chen-Yang Shen, Xiao-Ou Shu, Jacques Simard, Harald Surowy, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Soo Hwang Teo, Lauren R. Teras, Amanda E. Toland, Rob A. E. M. Tollenaar, Diana Torres, Gabriela Torres-Mejia, Melissa A. Troester, Therese Truong, Celine M. Vachon, Joseph Vijai, Clarice R. Weinberg, Camilla Wendt, Robert Winqvist, Alicja Wolk, Anna H. Wu, Taiki Yamaji, Xiaohong R. Yang, Jyh-Cherng Yu, Wei Zheng, Argyrios Ziogas, Elad Ziv, Alison M. Dunning, Douglas F. Easton, Harry Hemingway, Ute Hamann, Karoline B. Kuchenbaecker
Summary: This study identified 14 genes associated with breast cancer using gene-based aggregation analysis, including two newly discovered genes FMNL3 and AC058822.1. Furthermore, associations with established candidate genes like ESR1 were found through the collaboration of multi-ancestral cohorts, highlighting the importance of diversifying study cohorts. These findings provide new insights into the development of breast cancer.
Article
Oncology
Patricia Altea-Manzano, Ginevra Doglioni, Yawen Liu, Alejandro M. Cuadros, Emma Nolan, Juan Fernandez-Garcia, Qi Wu, Melanie Planque, Kathrin Julia Laue, Florencia Cidre-Aranaz, Xiao-Zheng Liu, Oskar Marin-Bejar, Joke Van Elsen, Ines Vermeire, Dorien Broekaert, Sofie Demeyer, Xander Spotbeen, Jakub Idkowiak, Aurelie Montagne, Margherita Demicco, H. Furkan Alkan, Nick Rabas, Carla Riera-Domingo, Francois Richard, Tatjana Geukens, Maxim De Schepper, Sophia Leduc, Sigrid Hatse, Yentl Lambrechts, Emily Jane Kay, Sergio Lilla, Alisa Alekseenko, Vincent Geldhof, Bram Boeckx, Celia de la Calle Arregui, Giuseppe Floris, Johannes V. Swinnen, Jean-Christophe Marine, Diether Lambrechts, Vicent Pelechano, Massimiliano Mazzone, Sara Zanivan, Jan Cools, Hans Wildiers, Veronique Baud, Thomas G. P. Gruenewald, Uri Ben-David, Christine Desmedt, Ilaria Malanchi, Sarah-Maria Fendt
Summary: The formation of pre-metastatic niche and high-fat diet can increase palmitate availability in future organs of metastases, promoting NF-kappa B acetylation and inducing metastatic signaling. Deletion of acetyltransferase and palmitoyltransferase reduces metastasis formation.
Meeting Abstract
Oncology
L. Kinget, S. Naulaerts, J. Govaerts, I. Vanmeerbeek, J. Sprooten, R. S. Laureano, E. Roussel, A. T. L. Verbiest, D. Lambrechts, B. Boeckx, J. Zucman-Rossi, M. Albersen, M. Baldewijns, S. Tejpar, B. Beuselinck, A. D. Garg
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew P. Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaih, Maite Verreault, Annette T. Byrne, Alice C. O'Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M. F. Dirven, Sieger Leenstra, Martine L. M. Lamfers
Summary: This study found that patient-derived glioma stem-like cells (GSCs) retain patient-unique gene expressions despite the loss of their natural environment. Drug screening using GSCs predicted patient response to temozolomide (TMZ) more specifically than the MGMT status alone. Transcriptome analysis identified potential biomarkers for TMZ sensitivity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Seppe Cambier, Fabio Beretta, Noemie Portner, Mieke Metzemaekers, Ana Carolina de Carvalho, Erik Martens, Janne Kaes, Celine Aelbrecht, Cato Jacobs, Pierre Van Mol, Els Wauters, Philippe Meersseman, Greet Hermans, Rafael Elias Marques, Bart Vanaudenaerde, Robin Vos, Joost Wauters, Mieke Gouwy, Paul Proost
Summary: CXCL12, which is present in the lungs and circulation of COVID-19 patients, undergoes rapid proteolytic processing and degradation. The proteolysis is mainly mediated by neutrophil elastase in COVID-19 BAL fluids with high proteolytic activity.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Article
Immunology
Simon Feys, Katrien Lagrou, Hanne Moon Lauwers, Koen Haenen, Cato Jacobs, Marius Brusselmans, Yves Debaveye, Greet Hermans, Martin Hoenigl, Johan Maertens, Philippe Meersseman, Marijke Peetermans, Isabel Spriet, Christophe Vandenbriele, Lore Vanderbeke, Robin Vos, Eric Van Wijngaerden, Alexander Wilmer, Joost Wauters
Summary: COVID-19-associated pulmonary aspergillosis (CAPA) occurs frequently in critically ill patients with COVID-19, especially in severely immunocompromised patients. The incidence of CAPA increases significantly during the vaccination era and is associated with higher mortality rates.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Oncology
Valerie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, Joao Sabino, Lara Crape, Michael Somers, Anne Hoorens, Joris Dutre, Triana Lobaton
Summary: This paper provides updated practice advice on the diagnosis and management of immune checkpoint inhibitor-induced gastrointestinal toxicity for gastroenterologists and oncologists. The use of immune checkpoint inhibitors in cancer immunotherapy has been shown to increase overall survival, but it also carries the risk of severe immune-mediated adverse events, particularly involving the gastrointestinal tract. The paper emphasizes the importance of early multidisciplinary approach and proposes criteria for diagnosis and treatment.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Cell Biology
Aurora Gomez-Vecino, Roberto Corchado-Cobos, Adrian Blanco-Gomez, Natalia Garcia-Sancha, Sonia Castillo-Lluva, Ana Martin-Garcia, Marina Mendiburu-Elicabe, Carlos Prieto, Sara Ruiz-Pinto, Guillermo Pita, Alejandro Velasco-Ruiz, Carmen Patino-Alonso, Purificacion Galindo-Villardon, Maria Linarejos Vera-Pedrosa, Jose Jalife, Jian-Hua Mao, Guillermo Macias de Plasencia, Andres Castellanos-Martin, Maria del Mar Saez-Freire, Susana Fraile-Martin, Telmo Rodrigues-Teixeira, Carmen Garcia-Macias, Julie Milena Galvis-Jimenez, Asuncion Garcia-Sanchez, Maria Isidoro-Garcia, Manuel Fuentes, Maria Begona Garcia-Cenador, Francisco Javier Garcia-Criado, Juan Luis Garcia-Hernandez, Maria Angeles Hernandez-Garcia, Juan Jesus Cruz-Hernandez, Cesar Augusto Rodriguez-Sanchez, Alejandro Martin Garcia-Sancho, Estefania Perez-Lopez, Antonio Perez-Martinez, Federico Gutierrez-Larraya, Antonio J. Carton, Jose Angel Garcia-Saenz, Ana Patino-Garcia, Miguel Martin, Teresa Alonso-Gordoa, Christof Vulsteke, Lieselot Croes, Sigrid Hatse, Thomas Van Brussel, Diether Lambrechts, Hans Wildiers, Hang Chang, Marina Holgado-Madruga, Anna Gonzalez-Neira, Pedro L. Sanchez, Jesu Perez Losada
Summary: Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, and identifying individuals at risk is challenging. In this study, the authors investigated intermediate molecular phenotypes (IMPs) associated with myocardial damage to determine CDA susceptibility. By analyzing a mouse cohort treated with doxorubicin and docetaxel, they identified genetic markers linked to IMPs and CDA. These markers were also found to be associated with CDA in cancer patients, highlighting their potential as predictive factors. Additionally, genetic risk scores were generated using machine-learning regression to personalize patient management.
Meeting Abstract
Oncology
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Karen Van Baelen, Maxim De Schepper, Coralie Poncet, Mauro Delorenzi, Marjanka K. Schmid, Emiel Rutgers, Laura Van't Veer, Martine Piccart, Fatima Cardoso, Giuseppe Viale, Ayse Bassez, Hanne Vos, Patrick Neven, Ines Nevelsteen, Kevin Punie, Hans Wildiers, Giuseppe Floris, Diether Lambrechts, Ann Smeets, Elia Biganzoli, Francois Richard, Christine Desmedt
Article
Medicine, Research & Experimental
Bruna M. Silva, Giovanni F. Gomes, Flavio P. Veras, Seppe Cambier, Gabriel V. L. Silva, Andreza U. Quadros, Diego B. Caetite, Daniele C. Nascimento, Camilla M. Silva, Juliana C. Silva, Samara Damasceno, Ayda H. Schneider, Fabio Beretta, Sabrina S. Batah, Icaro M. S. Castro, Isadora M. Paiva, Tamara Rodrigues, Ana Salina, Ronaldo Martins, Guilherme C. M. Cebinelli, Naira L. Bibo, Daniel M. Jorge, Helder I. Nakaya, Dario S. Zamboni, Luiz O. Leiria, Alexandre T. Fabro, Jose C. Alves-Filho, Eurico Arruda, Paulo Louzada-Junior, Rene D. Oliveira, Larissa D. Cunha, Pierre Van Mol, Lore Vanderbeke, Simon Feys, Els Wauters, Laura Brandolini, Andrea Aramini, Fernando Q. Cunha, Joerg Koehl, Marcello Allegretti, Diether Lambrechts, Joost Wauters, Paul Proost, Thiago M. Cunha
Summary: Activation of the C5a/C5aR1 pathway in COVID-19 patients can worsen the disease and lead to cytokine storm syndrome, organ dysfunction, and death. Inhibiting C5aR1 signaling can improve lung immunopathology, suggesting that C5aR1 antagonists may be useful for COVID-19 treatment.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Cell Biology
Stefan Naulaerts, Angeliki Datsi, Daniel M. Borras, Asier Antoranz Martinez, Julie Messiaen, Isaure Vanmeerbeek, Jenny Sprooten, Raquel S. Laureano, Jannes Govaerts, Dena Panovska, Marleen Derweduwe, Michael C. Sabel, Marion Rapp, Weiming Ni, Sean Mackay, Yannick Van Herck, Lendert Gelens, Tom Venken, Sanket More, Oliver Bechter, Gabriele Bergers, Adrian Liston, Steven De Vleeschouwer, Benoit J. Van Den Eynde, Diether Lambrechts, Michiel Verfaillie, Francesca Bosisio, Sabine Tejpar, Jannie Borst, Rudiger V. Sorg, Frederik De Smet, Abhishek D. Garg
Summary: Through multiomics analysis of CD8+ T cell features in multiple patient cohorts and tumor types, we have identified different hypofunctional states of tumor-associated CD8+ T cells, including exhausted CD8+ T cells in supportive tumor niches and hypofunctional CD8+ T cells in nonsupportive niches. These two types of hypofunctional states exhibit distinct characteristics, such as different T cell receptor repertoires and immunopeptidomes. Furthermore, dysfunctional CD4+:CD8+ T cell interactions and a wound healing-like chemokine profile were observed in glioblastoma. Immuno-oncology clinical trials showed that anti-programmed cell death protein 1 (PD-1) immunotherapy exacerbated the tolerogenic disparities in glioblastoma, while dendritic cell (DC) vaccines partially corrected them. Recipients of DC vaccines for glioblastoma demonstrated evidence of antigen-specific immunity.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Biochemical Research Methods
Jan Van Slambrouck, Charlotte Schoenaers, Lies Laenen, Xin Jin, Kurt Beuselinck, Ann Verdonck, Joost Wauters, Geert Molenberghs, Bart M. Vanaudenaerde, Robin Vos, Peter Mombaerts, Katrien Lagrou, Laurens J. Ceulemans
Summary: The ability to detect SARS-CoV-2 RNA or antigen in BAL fluid samples using point-of-care tests (POCTs) can reduce the risk of developing severe COVID-19 after lung transplantation.
JOURNAL OF VIROLOGICAL METHODS
(2024)